Advertisement

Monitoring Drug Resistance for Herpesviruses

  • Graciela Andrei
  • Pierre Fiten
  • Erik De Clercq
  • Robert Snoeck
  • Ghislain Opdenakker
Part of the Methods in Molecular Medicine™ book series (MIMM, volume 24)

Abstract

Herpes simplex type 1 (HSV-1) and type 2 (HSV-2), varicella-zoster virus (VZV) and human cytomegalovirus (CMV) cause diseases that are usually self-limiting in the immunocompetent host. However, HSV-1, HSV-2, VZV, and CMV are major causes of morbidity and mortality in the immunocompromised patient. Prolonged antiviral treatment is often required for the clinical management of herpesvirus infections in the immunocompromised patient, and this favors the emergence of drug-resistant strains. The isolation of acyclovir-resistant (ACVr) HSV-1, HSV-2, and VZV strains as well as ganciclovir-resistant (GCVr) CMV strains has been reported with increasing frequency and is a major concern (1, 2, 3). Resistance to foscarnet (phosphonoformic acid [PFA]), the drug of choice when ACV or GCV fails, has also been described in the clinic (4,5). Furthermore, double resistance to both GCV and PFA (for CMV) and to both ACV and PFA (for HSV) has been observed in immuno-compromised patients after sequential and concomitant treatment with either or both drugs.

Keywords

Plaque Reduction Assay SacI Restriction Enzyme Human Embryonic Lung Cell Acyclic Nucleoside Phosphonate Phosphonoformic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Field, A. K. and Biron, K. K. (1994) “The end of innocence” revisited: resistance of herpesviruses to antiviral drugs. Clin. Microbiol. Rev. 7, 1–13.PubMedGoogle Scholar
  2. 2.
    Anonymous (1996) Drug resistance in cytomegalovirus: current knowledge and implications for patient management. J. Acquir. Immune Defic. Syndr. Hum. Retrovir. 12, S1–SS22.Google Scholar
  3. 3.
    Coen, D. M. (1991) The implicatons of resistance to antiviral agents for herpesvirus drug targets and drug therapy. Antiviral Res. 15, 287–300.CrossRefPubMedGoogle Scholar
  4. 4.
    Coen, D. M. (1995) Nucleosides and foscarnet—mechanisms, in Antiviral Drug Resistance (Richman, D. D., ed.), Wiley, Chichester, pp. 81–102.Google Scholar
  5. 5.
    Safrin, S. (1995) Nucleosides and foscarnet—clinical aspects, in Antiviral Drug Resistance (Richman, D. D., ed.), Wiley, Chichester, pp. 103–122.Google Scholar
  6. 6.
    Snoeck, R., Andrei, G., Girard, M., Silverman, A., Hedderman, A., Balzarini, J., Sadzot-Delvaux, C., Tricot, G., Clumeck, N., and De Clercq, E. (1994) Successful treatment of progressive mucocutaneous infection due to acyclovir-and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine (HPMPC). Clin. Infect. Dis. 18, 570–578.PubMedGoogle Scholar
  7. 7.
    Hitchcock, M. J. M., Jaffe, H. S., Martin, J. C., and Stagg, R. J. (1996) Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Res. 7, 115–127.Google Scholar
  8. 8.
    Collins, P. and Darby, G. (1991) Laboratory studies of herpes simplex virus strains resistant to acyclovir. Rev. Med. Virol. 1, 19–28.CrossRefGoogle Scholar
  9. 9.
    Andrei, G., Snoeck, R., and De Clercq, E. (1995) Susceptibilities of several drug-resistant herpes simplex virus type 1 strains to alternative antiviral compounds. Antimicrob. Agents Chemother. 39, 1632–1635.PubMedGoogle Scholar
  10. 10.
    Snoeck, R., Andrei, G., and De Clercq, E. (1996) Patterns of resistance and sensitivity to antiviral compounds of drug-resistant strains of human cytomegalovirus selected in vitro. Eur. J. Clin. Microbiol. Infect. Dis. 15, 574–579.CrossRefPubMedGoogle Scholar
  11. 11.
    Sambrook, J., Fritsch, E. F., and Maniatis, T. (eds.) (1989) Molecular Cloning. A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.Google Scholar
  12. 12.
    Morfin, F., Snoeck, R., Andrei, G., and De Clercq, E. (1996) Phenotypic resistance of herpes simplex virus type 1 strains selected in vitro with antiviral compounds and combinations thereof. Antiviral Chem. Chemother. 7, 270–275.Google Scholar
  13. 13.
    Andrei, G., Snoeck, R., and De Clercq, E. (1994) Human brain tumour cell lines as cell substrate to demonstrate sensitivity/resistance of herpes simplex virus types 1 and 2 to nucleoside analogues. Antiviral Chem. Chemother. 5, 263–270.Google Scholar

Copyright information

© Humana Press Inc. 2000

Authors and Affiliations

  • Graciela Andrei
    • 1
  • Pierre Fiten
    • 1
  • Erik De Clercq
    • 1
  • Robert Snoeck
    • 1
  • Ghislain Opdenakker
    • 1
  1. 1.Rega Institute for Medical ResearchKatholieke UniversiteitLeuvenBelgium

Personalised recommendations